FY2025 Earnings Estimate for Bruker Issued By Zacks Research

Bruker Corporation (NASDAQ:BRKR) – Stock analysts at Zacks Research reduced their FY2025 earnings estimates for Bruker in a research note issued on Tuesday, January 6th. Zacks Research analyst Team now forecasts that the medical research company will earn $1.89 per share for the year, down from their previous estimate of $1.90. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker’s Q4 2025 earnings at $0.65 EPS and FY2027 earnings at $2.44 EPS.

BRKR has been the subject of a number of other reports. The Goldman Sachs Group began coverage on Bruker in a research report on Tuesday, December 9th. They set a “sell” rating and a $40.00 target price for the company. Rothschild Redb raised Bruker to a “strong-buy” rating in a research note on Thursday, November 20th. Cowen reiterated a “hold” rating on shares of Bruker in a research note on Wednesday. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a research report on Monday, December 29th. Finally, TD Cowen upped their price target on shares of Bruker from $42.00 to $53.00 and gave the stock a “hold” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $52.29.

Bruker Trading Down 1.0%

Shares of NASDAQ:BRKR opened at $52.48 on Thursday. The business’s 50 day simple moving average is $45.83 and its 200 day simple moving average is $39.63. Bruker has a 1 year low of $28.53 and a 1 year high of $64.64. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.85 and a quick ratio of 0.91. The company has a market capitalization of $7.97 billion, a P/E ratio of -328.00, a P/E/G ratio of 6.87 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The firm had revenue of $860.50 million during the quarter, compared to the consensus estimate of $847.40 million. During the same quarter in the previous year, the firm posted $0.60 EPS. The business’s revenue for the quarter was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 2nd. Investors of record on Monday, December 8th were given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Monday, December 8th. Bruker’s dividend payout ratio is currently -125.00%.

Insider Buying and Selling

In other Bruker news, Director John A. Ornell sold 6,233 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $39.00, for a total value of $243,087.00. Following the sale, the director owned 35,212 shares in the company, valued at $1,373,268. This trade represents a 15.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 27.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Nisa Investment Advisors LLC grew its position in Bruker by 377.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock worth $25,000 after acquiring an additional 487 shares during the last quarter. Allworth Financial LP boosted its stake in shares of Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares in the last quarter. Huntington National Bank grew its holdings in shares of Bruker by 750.0% during the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock worth $30,000 after purchasing an additional 645 shares during the last quarter. Spire Wealth Management acquired a new position in shares of Bruker in the second quarter valued at approximately $32,000. Finally, Parallel Advisors LLC raised its holdings in Bruker by 63.0% in the 2nd quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock valued at $37,000 after buying an additional 347 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Key Headlines Impacting Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker acquired the remaining 60% of TOFWERK, taking ownership to 100% — adding ultra-fast TOF mass‑spectrometry for small‑molecule applied markets (air quality, exposomics, foods/flavors). This expands Bruker’s addressable market and product set in applied MS, which could support medium‑term revenue growth if integration and commercialization go smoothly. Bruker Consolidates Ownership of TOFWERK
• Positive Sentiment: TD Cowen raised its price target from $42 to $53 and kept a Hold rating — a modest vote of confidence that helps support the stock’s valuation narrative. TD Cowen price-target update
• Positive Sentiment: Bruker will present at the J.P. Morgan Healthcare Conference — an opportunity for management to provide updates on TOFWERK integration, FY2025 outlook (company guidance: $1.85–$1.90 EPS), and strategic priorities that could influence sentiment. Bruker to Present at J.P. Morgan Healthcare Conference
• Neutral Sentiment: Media/analysis pieces are weighing Bruker’s life‑sciences exposure and mixed valuation signals — useful context but not immediate catalysts. Valuation analysis
• Negative Sentiment: Zacks Research trimmed Q4 2025, FY2025 and FY2027 EPS estimates slightly (Q4 2025: $0.66→$0.65; FY2025: $1.90→$1.89; FY2027: $2.45→$2.44) and retains a Hold — modest downward revisions that can press near‑term sentiment, especially given recent mixed revenue and margin trends.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.